IN FOCUS

More than 10 new drugs are set to flood the IgA nephropathy market. Previously, the IgA nephropathy treatment market was relatively quiet, as the pathogenesis was unclear and treatment approaches only addressed symptoms rather than the root cause.
FINANCE
VIEW ALL
September 15, 2025
ArkBio submits to HKEX, specializing in respiratory and pediatric disease treatmentsOn September 15, Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with J.P. Morgan and CITIC Securities acting as joint sponsors. Founded in 2013, ArkBio specializes in respiratory and pediatric diseases, with a pipeline of six drug candidates. Key products include: - Ziresovir, the world’s first RSV therapy under NDA review; - AK0610, a Phase II monoclonal antibody for RSV prevention; - AK3280, in Phase II trials for idiopathic pulmonary fibrosis; - AK0901, an ADHD drug at the NDA stage. Financially, ArkBio reported losses of RMB 270 million (2023), RMB 197 million (2023), RMB 87.5 million (mid-2025), and RMB 104 million (mid-2025).
MORE
September 14, 2025
StarryGene, a Chinese gene therapy company, has completed its A2 round of financingINNOVATION
VIEW ALL
September 15, 2025
Merck's Letermovir Tablets (II) approved in China, adding a new option for CMV preventionOn September 15, 2025, Merck announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor, PREVYMIS®, in a new formulation, Letermovir Tablets (II), has been approved by the National Medical Products Administration (NMPA) of China.
September 16, 2025
World's first generic Degarelix approved for marketing September 15, 2025
Easton Pharmaceuticals lands exclusive rights to a RMB 500 million blockbuster drugMORE
September 11, 2025
Another major new drug approved for lung cancer in China September 11, 2025
Medical device BD is experiencing rapid growthMNC CHINA LENS
VIEW ALL
September 11, 2025
Eli Lilly's BTK Inhibitor Enters the Autoimmune Disease Therapeutic FieldOn September 11th, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that Eli Lilly has registered a Phase I/II, dose-finding study (CTR20253341) in China, which aims to evaluate the safety and efficacy of pitobrutinib in adult patients with immune thrombocytopenia.
September 12, 2025
AstraZeneca's long-acting C5 complement inhibitor Weilirui® launched in China September 12, 2025
CSPC Holdings: HER2 Bispecific antibody submitted for marketing approval September 11, 2025
Medical device BD is experiencing rapid growthMORE
September 06, 2025
Johnson & Johnson Announces a Major Collaboration September 04, 2025
$5.4 Billion: Novartis bets on a Chinese siRNA drugINSIGHT
VIEW ALL
September 15, 2025
With RMB 8 billion invested in four years: is Changchun High-Tech's innovative drug research finally paying off?The stock price of Changchun High-Tech has regained strength after a prolonged period of weakness, primarily driven by its core subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci), and its sustained investment in innovative drug development. Since 2021, GenSci has invested nearly RMB 8 billion in R&D to seek new growth drivers.
September 16, 2025
The IgA nephropathy market: a RMB 500 million-monthly blue ocean turns redMORE
September 12, 2025
HK$578 million! Another innovative pharmaceutical company raises funds at a discount September 12, 2025
In Vivo CAR-T Fuels Upstream Industry Players?RESEARCH
VIEW ALL
September 04, 2025
Kaiyuan Securities: Tracking Global Cutting-Edge Progress in the Weight Loss Sector (II) — Orforglipron Leads the Global Small-Molecule GLP-1RA Race as Domestic Pipeline Value Gradually EmergesSmall-molecule GLP-1RAs offer numerous advantages, including low cost, unrestricted usage scenarios, and no need for cold-chain transportation, giving them broad development prospects. In the small-molecule GLP-1RA race, Eli Lilly and Company’s Orforglipron has completed global Phase III trials for both diabetes and obesity, maintaining a leading position worldwide. AstraZeneca’s AZD5004, Roche’s CT-996, Lilly’s Naperiglipron, and Terns’ TERN-601 have all entered Phase II, with overall progress advancing rapidly. Among domestic companies, Hengrui Pharma, Huadong Medicine, and Ascletis Pharma, among others, are actively building small-molecule GLP-1RA pipelines. In recent years, this track has witnessed multiple high-profile BD transactions, and its growth momentum continues to strengthen.

September 03, 2025
2025 Chemical Pharmaceutical Enterprises Organizational Efficiency ReportAs of August 8, 2025, Shunwei Consulting collected organizational effectiveness data for 158 publicly listed chemical pharmaceutical companies through databases such as iFind. Among these, 111 are finished-dosage chemical drug companies and 47 are active pharmaceutical ingredient (API) companies.
Considering both company influence and revenue, companies with negative net profit (e.g., BeOne Medicines, Nenter) were excluded. From the remaining A-share listed companies, the top 10 chemical pharmaceutical companies by revenue were selected as benchmark enterprises for organizational effectiveness analysis.
To provide a comprehensive view of the industry, the selected companies cover various segments: innovative drug R&D (e.g., Hengrui Medicine, Humanwell Healthcare), high-end generics and internationalized formulations (e.g., Fosun Pharma, Kelun Pharma), and specialty APIs and complex formulations (e.g., Apeloa Pharmaceuticals, Livzon Group).

September 02, 2025
Global Healthcare Investment and Financing Monthly Report for August 2025In August 2025, a total of 150 financing events occurred globally in the healthcare sector (excluding IPOs, private placements, etc.), with a disclosed total financing amount of approximately USD 3.647 billion (around RMB 26.032 billion), according to incomplete statistics from VCBeat. Among these, the domestic market recorded 81 financing events with a total disclosed amount of approximately USD 942 million, while the overseas market recorded 69 financing events totaling approximately USD 2.705 billion.
Compared with July 2025 in terms of transaction amounts, number of financing events, and focus on emerging fields, the number of global healthcare financing events in August 2025 increased by approximately 11.11% month-on-month, while the total financing amount fell sharply by about 47.27%.
Regarding large financing events, 10 deals exceeded USD 100 million this month, with a cumulative financing amount of USD 1.511 billion. Among these, 9 occurred overseas and 1 domestically. The 10 companies are:
Kriya Therapeutics – gene therapy drug developer
EliseAI – healthcare system developer
Strand Therapeutics – biopharmaceutical company
Minghui Pharma – innovative drug developer
Apreo Health – device developer for emphysema treatment
Wugen – cell therapy developer
SetPoint Medical – developer of novel bioelectronic medical therapies
Restor3d – 3D-printed implant supplier
Eight Sleep – sleep health service provider
Nudge – developer of ultrasonic phased-array equipment
RANKING
VIEW ALL
September 16, 2025
Top innovative healthcare assets in China ranked for August 2025
August 05, 2025
Top innovative healthcare assets in China ranked for July 2025
July 05, 2025
Top innovative healthcare assets in China ranked for June 2025
May 10, 2025
Future Healthcare Rankings in China Top Ten Healthcare Industry Service Chain Companies in 2025Subscribe to our Newsletter Now
Exclusive updates and insights on healthcare innovation and Chinese market straight to your inbox